You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Merck
Colorcon
Moodys
Mallinckrodt

Last Updated: August 13, 2020

DrugPatentWatch Database Preview

ACETAZOLAMIDE SODIUM Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Acetazolamide Sodium patents expire, and when can generic versions of Acetazolamide Sodium launch?

Acetazolamide Sodium is a drug marketed by Emcure Pharms Ltd, Hospira, Mylan Asi, Par Sterile Products, West-ward Pharms Int, Xgen Pharms, and Zydus Pharms. and is included in seven NDAs.

The generic ingredient in ACETAZOLAMIDE SODIUM is acetazolamide sodium. There are ten drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the acetazolamide sodium profile page.

US ANDA Litigation and Generic Entry Outlook for Acetazolamide Sodium

A generic version of ACETAZOLAMIDE SODIUM was approved as acetazolamide sodium by WEST-WARD PHARMS INT on February 28th, 1995.

  Start Trial

Drug patent expirations by year for ACETAZOLAMIDE SODIUM
Recent Clinical Trials for ACETAZOLAMIDE SODIUM

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Azienda Ospedaliero-Universitaria di ParmaPhase 4
University of ParmaPhase 4
Azienda Unità Sanitaria Locale Reggio EmiliaPhase 4

See all ACETAZOLAMIDE SODIUM clinical trials

Pharmacology for ACETAZOLAMIDE SODIUM

US Patents and Regulatory Information for ACETAZOLAMIDE SODIUM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Emcure Pharms Ltd ACETAZOLAMIDE SODIUM acetazolamide sodium INJECTABLE;INJECTION 202693-001 Dec 19, 2014 DISCN No No   Start Trial   Start Trial   Start Trial
Zydus Pharms ACETAZOLAMIDE SODIUM acetazolamide sodium INJECTABLE;INJECTION 206533-001 Apr 15, 2019 AP RX No No   Start Trial   Start Trial   Start Trial
Par Sterile Products ACETAZOLAMIDE SODIUM acetazolamide sodium INJECTABLE;INJECTION 205358-001 Jun 20, 2017 DISCN No No   Start Trial   Start Trial   Start Trial
Hospira ACETAZOLAMIDE SODIUM acetazolamide sodium INJECTABLE;INJECTION 040108-001 Oct 30, 1995 DISCN No No   Start Trial   Start Trial   Start Trial
Mylan Asi ACETAZOLAMIDE SODIUM acetazolamide sodium INJECTABLE;INJECTION 200880-001 May 9, 2012 AP RX No No   Start Trial   Start Trial   Start Trial
Xgen Pharms ACETAZOLAMIDE SODIUM acetazolamide sodium INJECTABLE;INJECTION 040784-001 Dec 10, 2008 AP RX No Yes   Start Trial   Start Trial   Start Trial
West-ward Pharms Int ACETAZOLAMIDE SODIUM acetazolamide sodium INJECTABLE;INJECTION 040089-001 Feb 28, 1995 AP RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Dow
Moodys
Colorcon
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.